This study focuses on patients with Newly Diagnosed Multiple Myeloma, a type of blood cancer that develops in plasma cells found in bone marrow. The research evaluates a treatment called ciltacabtagene autoleucel (also known as cilta-cel), which is a specialized therapy that uses a patient’s own modified immune cells to fight cancer cells.
The treatment involves collecting the patient’s own T cells (a type of immune cell), which are then genetically modified in a laboratory to recognize and attack cancer cells. These modified cells are later given back to the patient through an intravenous infusion. The purpose of this study is to evaluate how well this treatment works when given with a modified preparation regimen that excludes a specific medication called fludarabine.
During the study, patients will receive their modified immune cells as a single infusion. The cells are stored in special freezing bags and will be thawed before being given to the patient. The treatment is part of a category of therapies known as cell therapy, which represents an advanced form of cancer treatment where the patient’s own immune system is enhanced to fight the disease.
Spain 
